Former CEO, Pyxis Oncology
Search every verified Lara Sullivan interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Lara Sullivan, M.D., former CEO of Pyxis Oncology, discussed her leadership approach and the company's pipeline in a May 2022 episode of the Business of Biotech podcast. She described Pyxis Oncology as a clinical-stage antibody-drug conjugate and immunotherapy company, noting that its lead candidates, PYX-106 and PYX-201, were expected to enter phase one trials for indications including thyroid, head and neck, non-small-cell lung cancer, and breast cancer. Sullivan also reflected on her career, including her time at Pfizer and her role in launching SpringWorks Therapeutics, and advocated for mentorship and apprenticeship-style training in biotech executive development. In the same interview, Sullivan spoke about portfolio management and risk diversification, comparing risk to energy in that it takes different forms across technical and commercial dimensions. She also commented on the biotech funding environment, stating that after a two-year global pandemic, the industry faced a "two-year biotech pandemic," with bankers estimating it would take 18 to 24 months to clear excess from the system. She noted that Pyxis Oncology was among the last IPOs to proceed before market conditions shifted.
Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies.
00:00 – Intro 00:16 – Dr. Lara Sullivan's Background 01:40 – Journey into Innovation - From Consulting to Founding Pyxis Oncology 03:17 – Bridging Medicine and Finance: Dr. Lara Sullivan's MBA Journey at Wharton 05:45 – Choosing Business over Medicine 06:25 – From Medical Family to Business World 07:27 –Navigating Career Choices: From Psychiatry to Business 09:30 – Journey through Different Communities 10:46 – Embracing Sports and Community 12:08 – Exploring Paths: From Chemistry to Comparative Literature 16:20 – The Intersection of Science and Art: Unleashing Creativity in Biotech 18:44 – Exp…
To fully appreciate the work Pyxis Oncology is doing in its development of site-specific ADCs for a number of oncological indications under the leadership of Lara Sullivan, M.D., you need to understand the work that shaped her leadership style. On this episode of the Business of Biotech, Dr. Sullivan shares the science and technology driving progress at Pyxis, but she also serves up a master class on change management, honed during her tenure managing high-stakes product portfolios at Pfizer. If you want to be a better leader, don't miss this one. And for more on Dr. Sullivan's journey, read t…
Pyxis Oncology CEO Dr. Lara Sullivan joins Jill Malandrino on Nasdaq #TradeTalks to discuss going public on Nasdaq and therapeutics for difficult-to-treat cancers.
Sign in to search the full transcript archive, filter by topic, and access every quote from Lara Sullivan.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans